Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Impact of Different In Vivo T Cell Depletion Strategies on Outcomes Following Hematopoietic Stem Cell Transplantation for Idiopathic Aplastic Anaemia: A Study on Behalf of the EBMT SAA Working Party

Sujith Samarasinghe, MD PhD, Simona Iacobelli, Cora Knol, Rose-Marie Hamladji, Gerard Socie, MD PhD, Mahmoud Aljurf, MD MPH, Mickey Koh, MD, Henrik Sengeloev, Jean-Hugues Dalle, PhD MD, Stephen Robinson, Andrea Bacigalupo, MD, Joan H Veelken, Dietrich Beelen, MD, Ghulam J Mufti, FRCP, FRCPath, John A Snowden, MD FRCP, FRCPath, Didier Blaise, MD PhD, Judith C.W. Marsh, MD, Carlo Dufour, MD, Antonio M Risitano, MD PhD

Blood (2015) 126 (23): 1210.

https://doi.org/10.1182/blood.V126.23.1210.1210

Published: 2015

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Severe Auto-Immune Disease Adult Patients: Analysis of Outcomes from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGMT-TC) in Light of the European Society for Blood and Marrow Transplantation (EBMT) Activity

Perrine Guillaume-Jugnot, MD, Zora Marjanovic, Myriam Labopin, MD, Louis Terriou, MD, Christophe Deligny, Bruno Lioure, MD, Thierry Martin, Veronique Leblond, MD PhD, Gregory Pugnet, Didier Blaise, Régis Peffault de Latour, MD, Ibrahim Yakoub-Agha, MD PhD, John A Snowden, MD FRCP, FRCPath, Dominique Farge, PhD MD

Blood (2015) 126 (23): 1985.

https://doi.org/10.1182/blood.V126.23.1985.1985

Published: 2015

Journal Articles

Outcomes Following Salvage Autologous Stem Cell Transplant (ASCT2) Vs Low Dose Alkylating Consolidation Therapy Following Bortezomib-Containing Re-Induction for Relapsed Multiple Myeloma (MM) May be Dependent on Age and Symptomatic Status Initiation of Re-Induction: Results from the Myeloma X (Intensive) Trial

John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, David A Cairns, Cathy Williams, A Hockaday, J. D. Cavenagh, MD MRCP, John A Snowden, MD FRCP, FRCPath, Christopher Parrish, MD, Kwee L Yong, MBChB, PhD, Jim Cavet, FRCPath, Hannah Hunter, Jennifer Bird, Guy Pratt, MD, Sally Chown, Earnest Heartin, Sheila J.M. O'Connor, Julia Brown, PhD, Curly Morris, MD, Gordon Cook, MD PhD

Blood (2015) 126 (23): 1981.

https://doi.org/10.1182/blood.V126.23.1981.1981

Published: 2015

Journal Articles

Patient-Reported Outcomes (PRO) in the Setting of Relapsed Myeloma: The Influence of Treatment Strategies and Genetic Variants Predict Quality of Life and Pain Experience

Sam H Ahmedzai, MBChB BSc FRCP, John A Snowden, MD FRCP, FRCPath, Angela Cox, BA MA PhD, David A Cairns, Cathy D Williams, Anna Hockaday, Jamie Cavenagh, Christopher Parrish, MD, Kwee L Yong, MBChB, PhD, Jim Cavet, FRCPath, Hannah Hunter, Jennifer Bird, John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, Julia Brown, PhD, Curly Morris, MD, Gordon Cook, MD PhD

Blood (2015) 126 (23): 3180.

https://doi.org/10.1182/blood.V126.23.3180.3180

Published: 2015

Journal Articles

A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial

Gordon Cook, MD PhD, Cathy Williams, David A Cairns, Anna Hockaday, Jamie Cavenagh, John A Snowden, MD FRCP, FRCPath, Christopher Parrish, MD, Kwee L Yong, MBChB, PhD, Jim Cavet, FRCPath, Hannah Hunter, Jennifer Bird, Guy Pratt, MD, Sally Chown, Earnest Heartin, Sheila J.M. O'Connor, John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, Julia Brown, PhD, Curly Morris, MD

Blood (2015) 126 (23): 394.

https://doi.org/10.1182/blood.V126.23.394.394

Published: 2015

Journal Articles

Does Ex Vivo CD34+ Cell Selection Change the Outcome of Systemic Sclerosis Patients Treated with Autologous Hematopoietic Stem Cell Transplantation (AHSCT), an Adwp EBMT Study?

Maria Carolina Oliveira, MD PhD, Myriam Labopin, MD, Jörg Henes, MD PhD, John Moore, MD, Nicoletta Del Papa, MD PhD, Ricca Stanciu, Ioanna Sakellari, MD PhD, Roland Schroers, MD, Hans Ulrich Scherer, MD, Slawomira Kyrcz-Krzemien, MD PhD Prof., Thomas Daikeler, MD, Tobias Alexander, Jürgen Finke, MD, Manuela Badoglio, John A Snowden, MD FRCP, FRCPath, Dominique Farge, MD PhD

Blood (2014) 124 (21): 2517.

https://doi.org/10.1182/blood.V124.21.2517.2517

Published: 2014

Journal Articles

Methotrexate Is a Suppressor of JAK/STAT Pathway Activation Which Inhibits JAK2V617F Induced Signalling

Sally J Thomas, BA BM BCh MRCP(UK), Katherine Fisher, MSci DPhil, Stephen Brown, BSc PhD, John A Snowden, MD FRCP, FRCPath, Sarah Danson, BMedSci BMBS MSc PhDFRCP, Martin Zeidler, BSc DPhil

Blood (2014) 124 (21): 4577.

https://doi.org/10.1182/blood.V124.21.4577.4577

Published: 2014

Journal Articles

Unrelated Cord Blood Transplantation (UCBT) In Adults In The UK: Evolution, Experience and Outcomes. A Retrospective Analysis On Behalf Of The British Society of Blood and Marrow Transplantation (BSBMT) and Eurocord

John A Snowden, MD, FRCP, FRCPath, Robert Danby, MRCP, Annalisa Ruggeri, MD, David I Marks, Rachael E Hough, MD, Antonio Pagliuca, Michael Potter, MD PhD, Nigel Russell, MD, Charles Craddock, MD DPhil, Andrew Clark, Eliane Gluckman, MD, Gordon Cook, MD, PhD, Bronwen E. Shaw, MBChB, MRCP, PhD, FRCPath, Vanderson Rocha, MD, PhD

Blood (2013) 122 (21): 3394.

https://doi.org/10.1182/blood.V122.21.3394.3394

Published: 2013

Journal Articles

Interphase FISH Analysis Of Multiple Myeloma Molecular Risk At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Gordon Cook, MD, PhD, John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Cathy D. Williams, MBBS, MCRP, FRCPath, David A Cairns, PhD, Marie Fletcher, Christopher Parrish, MD, James D. Cavenagh, MD, John A Snowden, MD, FRCP, FRCPath, Sheila J O'Connor, Roger G Owen, MD, Julia Brown, MB, Treen Morris

Blood (2013) 122 (21): 1884.

https://doi.org/10.1182/blood.V122.21.1884.1884

Published: 2013

Journal Articles

Outcome Of Pregnancy After Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Autoimmune Diseases (AD): A Retrospective Study Of The EBMT Autoimmune Diseases Working Party (ADWP)

Emilian Snarski, John A Snowden, MD, FRCP, FRCPath, Manuela Badoglio, Kristina Carlson, Joachim Burman, MD, Maria Carolina Oliveira, John Moore, Jeffrey Tan, Montserrat Rovira, MD, Richard E Clark, MD, Albert Saiz, Sondess Hadj Khelifa, Alessandra Crescimanno, Lynne Laing, Maurizio Musso, Thierry Martin, Dominique Farge, MD

Blood (2013) 122 (21): 4640.

https://doi.org/10.1182/blood.V122.21.4640.4640

Published: 2013

Journal Articles

The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Ruth M de Tute, MSc, David A Cairns, PhD, Marie Fletcher, Roger G Owen, MD, Andy Rawstron, PhD, Sheila J.M. O'Connor, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, John A Snowden, MD, FRCP, FRCPath, J. D. Cavenagh, MD, MRCP, Christopher Parrish, MA, MB, BChir, MRCP, Treen Morris, Julia MB Brown, Gordon Cook, MD, PhD

Blood (2013) 122 (21): 3378.

https://doi.org/10.1182/blood.V122.21.3378.3378

Published: 2013

Journal Articles

A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Gordon Cook, MD, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, David A Cairns, PhD, Marie Fletcher, J. D. Cavenagh, MD, MRCP, John A Snowden, MD, FRCP, FRCPath, Christopher Parrish, MD, John Ashcroft, Kwee L Yong, PhD, Jim Cavet, FRCPath, Hannah Hunter, MB, FRCPath, MRCP, Jennifer Bird, Sheila J O'Connor, Julia MB Brown, Treen Morris

Blood (2013) 122 (21): 765.

https://doi.org/10.1182/blood.V122.21.765.765

Published: 2013

NARROW

Impact of Different In Vivo T Cell Depletion Strategies on Outcomes Following Hematopoietic Stem Cell Transplantation for Idiopathic Aplastic Anaemia: A Study on Behalf of the EBMT SAA Working Party

Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Severe Auto-Immune Disease Adult Patients: Analysis of Outcomes from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGMT-TC) in Light of the European Society for Blood and Marrow Transplantation (EBMT) Activity

Patient-Reported Outcomes (PRO) in the Setting of Relapsed Myeloma: The Influence of Treatment Strategies and Genetic Variants Predict Quality of Life and Pain Experience

A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial

Does Ex Vivo CD34+ Cell Selection Change the Outcome of Systemic Sclerosis Patients Treated with Autologous Hematopoietic Stem Cell Transplantation (AHSCT), an Adwp EBMT Study?

Methotrexate Is a Suppressor of JAK/STAT Pathway Activation Which Inhibits JAK2V617F Induced Signalling

Unrelated Cord Blood Transplantation (UCBT) In Adults In The UK: Evolution, Experience and Outcomes. A Retrospective Analysis On Behalf Of The British Society of Blood and Marrow Transplantation (BSBMT) and Eurocord

Interphase FISH Analysis Of Multiple Myeloma Molecular Risk At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Outcome Of Pregnancy After Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Autoimmune Diseases (AD): A Retrospective Study Of The EBMT Autoimmune Diseases Working Party (ADWP)

The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only